🇺🇸 FDA
Pipeline program

ONC206 Powder

PNOC023

Phase 1 small_molecule active

Quick answer

ONC206 Powder for Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors is a Phase 1 program (small_molecule) at AXIM BIOTECHNOLOGIES, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
AXIM BIOTECHNOLOGIES, INC.
Indication
Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials